Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus

doi:10.5246/jcps.2021.08.057

Abstract

Abstract:

In the present study, we aimed to investigate the effects of linagliptin on inflammatory factors and carotid intima-media thickness (CIMT) in newly diagnosed type 2 diabetes mellitus (T2DM) patients with carotid atherosclerotic disease (CAD). A total of 326 patients with newly diagnosed T2DM complicated with CAD were randomly divided into two groups. There were 163 patients in the control group, who were treated with metformin monotherapy. There were 163 patients in the experimental group, who were treated with metformin in combination with linagliptin. The CIMT before and after treatment was measured by color Doppler ultrasound, and the contents of IL-6 and IL-1β before and after treatment were detected by ELISA. The levels of inflammatory factors and CIMT before and after treatment were compared between the two groups, and the correlation between IL-6, IL-1β and CIMT was studied. After 24 weeks of treatment, the levels of inflammatory factors and CIMT in the experimental group were significantly lower compared with the control group (P < 0.01), and the serum levels of IL-6 and IL-1β were positively correlated with CIMT. In the present study, we concluded that linagliptin could improve the levels of inflammatory factors and CIMT in newly diagnosed T2DM patients with CAD, and IL-6 and IL-1β might participate in the occurrence and development of CAD by influencing CIMT.

Key words: Linagliptin, Type 2 diabetes mellitus, Carotid atherosclerosis disease, Inflammatory factors, Carotid intima-media thickness

Supporting:

Rui Li, Yanru Kong. Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(8): 692-698.

Figures/Tables 5

References 18

[1]	Gupta, R.; Walunj, S.S.; Tokala, R.K.; Parsa, K.V.L.; Singh, S.K.; Pal, M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr. Drug Targets. 2009, 10, 71–87.
[2]	Hwang, H.J.; Jung, T.W.; Ryu, J.Y.; Hong, H.C.; Choi, H.Y.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Choi, K.M.; Choi, D.S.; Baik, S.H.; Yoo, H.J. Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes. Mol. Cell Endocrinol. 2014, 392, 1–7.
[3]	Li, R.; Song, L.H.; Liu, J.; Bai, Y.; Du, Y.M.; Lin, C.H.; Su, X.Y.; Yu, Z.X. Cardioprotective effect of Linagliptin on diabetic Wistar rats. J. Chin. Pharm. Sci. 2021, 30, 334–346.
[4]	Araki, E.; Unno, Y.; Tanaka, Y.; Sakamoto, W.; Miyamoto, Y. Long-term efficacy and safety of linagliptin in a Japanese population with type 2 diabetes Aged ≥ 60 years treated with basal insulin: a randomised trial. Adv. Ther. 2019, 36, 2697–2711.
[5]	Senchenkova, E.Y.; Russell, J.; Yildirim, A.; Granger, D.N.; Gavins, F.N.E. Novel role of T cells and IL-6 (interleukin-6) in angiotensin II-induced microvascular dysfunction. Hypertens. Dallas Tex. 2019, 73, 829–838.
[6]	Khan, R.; Rheaume, E.; Tardif, J.C. Examining the role of and treatment directed at IL-1β in atherosclerosis. Curr. Atheroscler. Rep. 2018, 20, 53.
[7]	Grzanka, M.; Matejko, B.; Szopa, M.; Kiec-Wilk, B.; Malecki, M.T.; Klupa, T. Assessment of newly proposed clinical criteria to Identify HNF1AMODY in patients with an initial diagnosis of type 1 or type 2 diabetes mellitus. Adv. Med. 2016, 2016, 1–3.
[8]	Zhu, Y.H.; Xian, X.M.; Wang, Z.Z.; Bi, Y.C.; Chen, Q.G.; Han, X.F.; Tang, D.Q.; Chen, R.J. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. 2018, 8, 80.
[9]	Li, J.J.; Zhao, X.Q.; Meng, X.; Lin, J.X.; Liu, L.P.; Wang, C.X.; Wang, A.X.; Wang, Y.L.; Wang, Y.J.;. High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome. Stroke. 2016, 47, 2025–2030.
[10]	Song, Y.X.; Dou, H.; Li, X.J.; Zhao, X.Y.; Li, Y.; Liu, D.; Ji, J.J.; Liu, F.; Ding, L.; Ni, Y.H.; Hou, Y.Y. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1β-primed mesenchymal stem cells against sepsis. STEM CELLS. 2017, 35, 1208–1221.
[11]	Qu, H.P.; Liu, Z.J.; Liu, J.L. Measurement of monocyte apoptosis, plasma IL-1β and PR3 activity as an approach to evaluate the immunological status in sepsis. Crit. Care. 2011, 15, 434.
[12]	Böni-Schnetzler, M.; Donath, M.Y. Increased IL-1β activation, the culprit not only for defective insulin secretion but also for insulin resistance? Cell Res. 2011, 21, 995–997.
[13]	Finucane, O.M.; Lyons, C.L.; Murphy, A.M.; Reynolds, C.M.; Klinger, R.; Healy, N.P.; Cooke, A.A.; Coll, R.C.; McAllan, L.; Nilaweera, K.N.; O’Reilly, M.E.; Tierney, A.C.; Morine, M.J.; Alcala-Diaz, J.F.; Lopez-Miranda, J.; O’Connor, D.P.; O’Neill, L.A.; McGillicuddy, F.C.; Roche, H.M. Monounsaturated fatty acid–enriched high-fat diets impede adipose NLRP3 inflammasome–mediated IL-1β secretion and insulin resistance despite obesity. Diabetes. 2015, 64, 2116–2128.
[14]	Tong, L.L.; Adler, S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgrad. Med. 2018, 130, 381–393.
[15]	Müller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; Holst, J.J.; Langhans, W.; Meier, J.J.; Nauck, M.A.; Perez-Tilve, D.; Pocai, A.; Reimann, F.; Sandoval, D.A.; Schwartz, T.W.; Seeley, R.J.; Stemmer, K.; Tang-Christensen, M.; Woods, S.C.; DiMarchi, R.D.; Tschöp, M.H. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130.
[16]	Ta, N.N.; Schuyler, C.A.; Li, Y.; Lopes-Virella, M.F.; Huang, Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 2011, 58, 157–166.
[17]	Nezu, T.; Hosomi, N.; Aoki, S.; Matsumoto, M. Carotid intima-media thickness for atherosclerosis. J. Atheroscler. Thromb. 2016, 23, 18–31.
[18]	Centurión, O.A. Carotid intima-media thickness as a cardiovascular risk factor and imaging pathway of atherosclerosis. Crit. Pathw. Cardiol. 2016, 15, 152–160.